Seres Therapeutics (MCRB) Misses Q1 EPS by 2c

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.57), $0.02 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits